May 18, 2021 10:32 AM EDT
R&D

No­vo Nordisk con­tin­ues push­ing be­yond di­a­betes, net­ting PhII win for for­mer Cor­vidia kid­ney pro­gram

Max Gelman

Senior Editor

As No­vo Nordisk con­tin­ues look­ing at ways to ex­pand be­yond its block­buster di­a­betes busi­ness, the Dan­ish phar­ma picked up some good news from a chron­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

A service from the Financial Times